逾百个品种已满足第十一批药品集采条件

Core Insights - The National Healthcare Security Administration (NHSA) plans to conduct the 11th batch of centralized drug procurement in the first half of the year, with over 130 drug varieties meeting the initial conditions for procurement [1][2] - The injectable drug Cefoperazone Sodium has a domestic sales revenue exceeding 4 billion yuan in 2023, with 37 companies meeting the evaluation criteria, indicating strong market competition [2][3] - The government aims to optimize drug procurement policies, enhancing quality assessment and regulation to ensure safer medication for the public [4] Group 1 - The NHSA has identified over 130 drug varieties that meet the criteria for centralized procurement, with 7 varieties having more than 30 companies that have passed the evaluation [1][2] - Cefoperazone Sodium injection leads the market with a sales revenue of approximately 4.4 billion yuan in 2023, ranking second among cephalosporin products [2] - The 11th batch of procurement is the first since the government report emphasized optimizing procurement policies, raising questions about potential adjustments to procurement rules [4] Group 2 - The draft proposal for optimizing drug procurement policies includes measures to prevent abnormal low pricing and ensure fair competition among companies [4] - The proposal also mentions that drugs under negotiation in the National Drug Catalog will generally not be included in the procurement scope, indicating a shift in policy [4] - Since the initiation of the "4+7" pilot program in November 2018, the NHSA has successfully procured 435 types of drugs, saving approximately 440 billion yuan in healthcare funds [4]